Pharmaceuticals Africa

Africa Cell and Gene Therapy CDMO Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Africa Cell and Gene Therapy CDMO Market Industry Trends and Forecast to 2034: Segmented by (Service, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $111.7 Mn Placeholder estimate
Estimate 2025 $135.7 Mn 1.6% of the global market
Projected 2034 $782.8 Mn 477% Adds $647.1 Mn over 9 forecast years
CAGR 2025–2034 21.5% Faster than 87% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Africa is 1.57% of the global market.
  • Among regions, the largest is North America at $4.81 Bn.
  • Fastest growing: Africa (this report) at 21.5% a year.
  • Africa ranks 6th of 6 by size among regions.

Market size projection

Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$647.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Cell and Gene Therapy CDMO Market market size by year, Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $111.7 Mn — —
2025 (base) $135.7 Mn +$24.0 Mn —
2026 (forecast) $164.8 Mn +$29.2 Mn +21.5%
2027 (forecast) $200.3 Mn +$35.4 Mn +47.6%
2028 (forecast) $243.3 Mn +$43.1 Mn +79.4%
2029 (forecast) $295.6 Mn +$52.3 Mn +117.9%
2030 (forecast) $359.2 Mn +$63.6 Mn +164.8%
2031 (forecast) $436.4 Mn +$77.2 Mn +221.7%
2032 (forecast) $530.3 Mn +$93.8 Mn +290.9%
2033 (forecast) $644.3 Mn +$114.0 Mn +374.9%
2034 (forecast) $782.8 Mn +$138.5 Mn +477%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Africa Cell and Gene Therapy CDMO Market Analysis at a glance
Market size, 2025$135.7 Mn placeholder estimate
Forecast, 2034$782.8 Mn placeholder estimate
Growth (CAGR), 2025–203421.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsService, product and end user (see all)
Key playersLonza Ltd, Catalent, Charles River Laboratories, WuXi AppTec, AGC Biologics and 1 more (see all)
Regulator in AfricaAMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Africa Cell and Gene Therapy CDMO Market Analysis Executive Summary

Cell and gene therapy CDMOs are contract companies that develop and manufacture cell and gene therapies for biotech and pharma firms.

Key segments of the cell and Gene Therapy CDMO market include service (Process Development, Clinical Manufacturing and Commercial Manufacturing) and product (Viral Vectors, Cell Therapies and Plasmid DNA).

Bar chart: Africa Cell and Gene Therapy CDMO market size, 2024–2034, placeholder estimates. $111.7 Mn in 2024, $135.7 Mn in 2025 and $782.8 Mn in 2034, 21.5% CAGR.
Africa Cell and Gene Therapy CDMO market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Africa Cell and Gene Therapy CDMO Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the cell and Gene Therapy CDMO market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the cell and Gene Therapy CDMO market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Cell and Gene Therapy CDMO Market in Africa

The cell and Gene Therapy CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cell and Gene Therapy CDMO Market in Africa

Cell and Gene Therapy CDMO in Africa: rules and payment

The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.⁠[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)⁠[2], PPB (Kenya)⁠[3] and SAHPRA (South Africa)⁠[4]. How care is paid for in some of these countries: universal health insurance (Egypt)⁠[5], the SHA (Kenya)⁠[6] and planned National Health Insurance (South Africa)⁠[7].

[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.

[2] Egyptian Drug Authority. Checked 14 Nov 2026.

[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[5] Universal Health Insurance Authority. Checked 14 Nov 2026.

[6] Social Health Authority. Checked 14 Nov 2026.

[7] National Department of Health. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cell and Gene Therapy CDMO. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cell and Gene Therapy CDMO right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cell and Gene Therapy CDMO in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cell and Gene Therapy CDMO market in Africa?
Placeholder estimate: about $135.7 Mn in 2025, rising to about $782.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cell and Gene Therapy CDMO market in Africa growing?
Placeholder estimate: about 21.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cell and Gene Therapy CDMO market report cover?
The report splits the market by service (Process Development, Clinical Manufacturing, Commercial Manufacturing, Testing), product (Viral Vectors, Cell Therapies, Plasmid DNA) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cell and Gene Therapy CDMO market?
Key players include Lonza Ltd, Catalent, Charles River Laboratories, WuXi AppTec, AGC Biologics and Samsung Biologics.
What is driving the Cell and Gene Therapy CDMO market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.
Who regulates Cell and Gene Therapy CDMO in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Africa

See all

Related on cell and gene therapy and drug development and manufacturing

See the topic